Effect of Hormonal Pre-treatment of Endometriosis on ICSI Outcome: A randomized Controlled trial
This randomized controlled trial demonstrates that pretreating women with endometriosis-associated infertility with dienogest for 3–6 months prior to their first ICSI cycle significantly improves oocyte maturation, fertilization rates, embryo quality, and both biochemical and clinical pregnancy outcomes compared to direct ICSI without hormonal pretreatment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For many women, the path to parenthood is blocked not by a lack of love or desire, but by a condition called endometriosis. This is a chronic, inflammatory disorder where tissue similar to the lining of the uterus grows outside the womb, often causing pain and making it difficult to conceive. When natural conception fails, doctors often turn to a powerful assisted technology called intracytoplasmic sperm injection, or ICSI. In this procedure, a single sperm is injected directly into an egg to create an embryo. However, the presence of endometriosis can sometimes compromise the quality of the eggs or the environment in which they develop, leading to lower success rates. Scientists have long wondered if calming this inflammation before starting the treatment could improve the outcome. One promising approach involves using a specific hormone medication, dienogest, to quiet the disease activity before the eggs are even collected, but until now, the evidence on whether this actually helps has been mixed and unclear.
To settle this question, a team of researchers at Cairo University conducted a carefully controlled experiment involving eighty-six women with endometriosis who were preparing for their first round of ICSI. The study was designed to be a fair comparison: the women were randomly split into two equal groups. One group received the hormone medication, dienogest, for a period of three to six months before beginning their fertility treatment. The other group skipped the medication entirely and went straight to the standard fertility treatment cycle. Both groups then underwent the exact same medical procedures for stimulating the ovaries, retrieving the eggs, and fertilizing them in the laboratory. This setup allowed the researchers to see if the months of pretreatment made a real difference in the quality of the eggs and the resulting pregnancies, without the results being skewed by other variables.
The results revealed a nuanced picture that challenges the idea that more eggs always equal better results. When the researchers counted the total number of eggs retrieved from the ovaries, there was no significant difference between the women who took the medication and those who did not; both groups produced roughly the same number of eggs. However, the quality of those eggs told a different story. The women who had taken dienogest pretreatment produced a significantly higher number of mature eggs ready for fertilization. More importantly, these mature eggs were much more likely to be successfully fertilized in the lab. The rate at which eggs turned into healthy, two-pronucleus embryos was nearly seven percentage points higher in the pretreated group. This improvement in the early stages of development translated into a higher number of high-quality embryos available for transfer.
These laboratory improvements led to tangible results in the clinic. The women who received the hormone pretreatment were significantly more likely to achieve a pregnancy. Specifically, nearly half of the women in the pretreatment group had a positive pregnancy test two weeks after embryo transfer, compared to just over a quarter of the women in the group that skipped the medication. Similarly, the rate of confirmed clinical pregnancies, where a gestational sac is seen on an ultrasound, was almost double in the group that took the medication. The study suggests that the medication did not work by creating more eggs, but rather by improving the environment so that the existing eggs were more likely to mature, get fertilized, and develop into healthy embryos capable of implanting.
Despite these encouraging findings, the researchers are careful to note that this study does not prove that the medication guarantees a baby, as the trial did not track live birth rates. The study was conducted at a single hospital with a relatively small number of participants, and the duration of the medication varied between three and six months for different patients. While the data strongly suggests that pretreating with dienogest can improve the odds of early pregnancy success for women with endometriosis, the authors conclude that more large-scale research is needed before this becomes a standard rule for everyone. The findings offer a hopeful glimpse into how managing the underlying disease might refine the success of fertility treatments, turning a difficult biological process into a more predictable one.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.